Niacin 500 mg by Natrol — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because its 500mg dose of niacin is more than 14 times the recommended maximum daily intake of 35mg.

Label Data

1 Tablet(s) Serving Size

100 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

500 mg (3130% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Hypromellose Microcrystalline Cellulose Stearic Acid Silicon Dioxide Methylcellulose Magnesium Stearate Glycerin Cellulose Gum

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegetarian Adult (18 - 50 Years) Dairy Free

Product Information

📋 Directions for Use

Directions: Take 1 tablet, one time daily, with a meal

⚠️ Warnings & Precautions

Warning: Consult your healthcare professional prior to use if you have or suspect a medical condition, are taking prescription drugs, or are pregnant or lactating.

Keep out of reach of children.

🧪 Formulation Notes

Natrol Niacin 500 mg Time Release: Niacin, also known as Vitamin B-3, helps promote healthy cholesterol already within the normal range 2-layer tablet-releases Niacin steadily to allow for zero flush

Heart health Promotes healthy cholesterol

No flush

No milk, egg, fish, crustacean shellfish, tree nuts, wheat, peanuts, soybeans, yeast, corn, artificial colors or flavors, added sugar, starch or preservatives

Additional Information

Store in a cool, dry place.

Product Details

UPC / SKU 0 47469 04835 8

DSLD Entry Date 2022-09-22

Product Type Vitamin

Form Tablet or Pill

Brand Natrol

DSLD ID 274493

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →